Jubira Plus 20mg/75mg Capsule is a combination medication containing Rosuvastatin 20mg and Aspirin 75mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and a history of or risk factors for atherosclerotic cardiovascular disease (ASCVD). Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and other lipid parameters, thereby slowing the progression of atherosclerosis. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and reduced platelet aggregation, which helps prevent thrombotic events such as myocardial infarction and stroke. The combined action of these agents provides both lipid-lowering and antithrombotic benefits, making Jubira Plus suitable for secondary prevention in patients at high cardiovascular risk. It is essential to use this medication under medical supervision, considering potential contraindications such as active bleeding, aspirin hypersensitivity, or severe hepatic impairment. Common adverse effects may include myalgia, gastrointestinal discomfort, or bleeding tendencies. Regular monitoring of lipid profiles, liver function tests, and signs of bleeding is recommended during therapy. Jubira Plus should be taken as prescribed, with adherence to lifestyle modifications for optimal cardiovascular risk reduction.